<VariationArchive RecordType="classified" VariationID="997720" VariationName="NC_000003.11:g.10167511_10193484del" VariationType="Deletion" Accession="VCV000997720" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-08-06" DateCreated="2021-02-28" MostRecentSubmission="2021-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="985435" VariationID="997720">
      <GeneList>
        <Gene Symbol="BRK1" FullName="BRICK1 subunit of SCAR/WAVE actin nucleating complex" GeneID="55845" HGNC_ID="HGNC:23057" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>3p25.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="10115675" stop="10127190" display_start="10115675" display_stop="10127190" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="10157332" stop="10168873" display_start="10157332" display_stop="10168873" Strand="+" />
          </Location>
          <OMIM>611183</OMIM>
        </Gene>
        <Gene Symbol="VHL" FullName="von Hippel-Lindau tumor suppressor" GeneID="7428" HGNC_ID="HGNC:12687" Source="submitted" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>3p25.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="10141778" stop="10153667" display_start="10141778" display_stop="10153667" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="10183318" stop="10195353" display_start="10183318" display_stop="10195353" Strand="+" />
          </Location>
          <OMIM>608537</OMIM>
          <Haploinsufficiency last_evaluated="2022-05-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=VHL">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2022-05-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=VHL">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NC_000003.11:g.10167511_10193484del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>3p25.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="10167511" stop="10193484" display_start="10167511" display_stop="10193484" variantLength="25974" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.11" sequenceAccession="NC_000003" sequenceVersion="11" change="g.10167511_10193484del" Assembly="GRCh37">
            <Expression>NC_000003.11:g.10167511_10193484del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000003.11:g.10167511_10193484del AND Von Hippel-Lindau syndrome" Accession="RCV001293277" Version="1">
        <ClassifiedConditionList TraitSetID="570">
          <ClassifiedCondition DB="MedGen" ID="C0019562">Von Hippel-Lindau syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-06-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2020-06-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2021-02-28" MostRecentSubmission="2021-02-28">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="570" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6116" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Von Hippel-Lindau syndrome</ElementValue>
                <XRef ID="Von+Hippel-Lindau+syndrome/7416" DB="Genetic Alliance" />
                <XRef ID="46659004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">VHL syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Von Hippel-Lindau</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">VHLS</ElementValue>
                <XRef Type="MIM" ID="193300" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Von Hippel-Lindau (VHL) syndrome is characterized by hemangioblastomas of the brain, spinal cord, and retina; renal cysts and clear cell renal cell carcinoma; pheochromocytoma, pancreatic cysts, and neuroendocrine tumors; endolymphatic sac tumors; and epididymal and broad ligament cysts. Cerebellar hemangioblastomas may be associated with headache, vomiting, gait disturbances, or ataxia. Spinal hemangioblastomas and related syrinx usually present with pain. Sensory and motor loss may develop with cord compression. Retinal hemangioblastomas may be the initial manifestation of VHL syndrome and can cause vision loss. Renal cell carcinoma occurs in about 70% of individuals with VHL and is the leading cause of mortality. Pheochromocytomas can be asymptomatic but may cause sustained or episodic hypertension. Pancreatic lesions often remain asymptomatic and rarely cause endocrine or exocrine insufficiency. Endolymphatic sac tumors can cause hearing loss of varying severity, which can be a presenting symptom. Cystadenomas of the epididymis are relatively common. They rarely cause problems, unless bilateral, in which case they may result in infertility.</Attribute>
                <XRef ID="NBK1463" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7855" />
                <XRef ID="7855" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000314230" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000553527" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528276" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562500" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569525" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552165" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000553528" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000595970" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592450" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530028" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552183" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569658" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301636</ID>
                <ID Source="BookShelf">NBK1463</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2010">
                <ID Source="PubMed">20664475</ID>
                <ID Source="pmc">3419007</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="KCRNC, 2013">
                <ID Source="PubMed">24319509</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Renal cell carcinoma genetics">
                <ID Source="PubMed">26389510</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Von Hippel-Lindau">
                <URL>https://www.cancer.gov/types/kidney/hp/renal-cell-carcinoma-genetics/vhl-syndrome</URL>
                <CitationText>PDQÂ® Cancer Genetics Editorial Board. PDQ Von Hippel-Lindau Disease. Bethesda, MD: National Cancer Institute. Updated &lt;03/08/2021&gt;. Accessed &lt;05/05/2021&gt;.</CitationText>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <XRef ID="892" DB="Orphanet" />
              <XRef ID="C0019562" DB="MedGen" />
              <XRef ID="MONDO:0008667" DB="MONDO" />
              <XRef Type="MIM" ID="193300" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2920965" SubmissionDate="2021-02-23" DateLastUpdated="2021-02-28" DateCreated="2021-02-28">
        <ClinVarSubmissionID localKey="NC_000003.11:g.10167511_10193484del|OMIM:193300" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001481867" DateUpdated="2021-02-28" DateCreated="2021-02-28" Type="SCV" Version="1" SubmitterName="Urologic Oncology Branch, National Institutes of Health" OrgID="507960" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-06-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="VHL" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000003.11:g.10167511_10193484del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="193300" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB9131516</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2920965" TraitType="Disease" MappingType="XRef" MappingValue="193300" MappingRef="OMIM">
        <MedGen CUI="C0019562" Name="Von Hippel-Lindau syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

